Oppenheimer Stick to Their Buy Rating for Pharming Group
Investing.com
Published Jan 01, 2021 04:02AM ET
Oppenheimer analyst Hartaj Singh maintained a Buy rating on Pharming Group on Thursday, setting a price target of EUR2.5, which is approximately 99.82% above the present share price of 1.54.
Singh expects Pharming Group to post earnings per share (EPS) of 0.01 for the first quarter of 2021.
The current consensus among 0 TipRanks analysts is for a Hold rating of shares in Pharming Group, with an average price target of .
The analysts price targets range from a high of to a low of .
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of 46.12 million and a net profit of 18.83 million. The company's market cap is 1 billion.
According to TipRanks.com, Oppenheimer analyst Hartaj Singh is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.4% and a 44.71% success rate.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.